Quest Diagnostics reported Q1 2026 revenue of $2.90 billion (+9.2% year-over-year), reported diluted EPS of $2.24 (+15.5%), and raised full-year guidance. The 10-Q filed April 22, 2026 decomposes the growth bluntly: total volume +10.9% year-over-year, revenue per requisition -1.30%, and roughly 7 percentage points of the 10.8% organic volume growth came from two specific contract relationships — Fresenius Medical Care end-stage renal disease and the Corewell Health Collaborative Lab Solutions. Excluding those two relationships, organic volume grew only 3.8% and the underlying clinical revenue per requisition rose approximately 2.5%. The segment footnote shows DIS operating margin expanded only 15 basis points while consolidated operating margin expanded 73 basis points, a gap created by a $11 million reduction in general corporate activities expense. Equity-method investee earnings collapsed from $18 million to $4 million — a silent ~$0.10 per share drag not addressed in management's adjusted-EPS bridge.
Abbott Laboratories reported $44.3 billion in revenue and a 52nd consecutive dividend increase — the kind of headline that signals a diversified compounder. But the 10-K's segment footnotes reveal that Medical Devices generates 61% of segment operating income, the $23 billion Exact Sciences acquisition targets the lowest-return division, and 1,760 infant formula lawsuits carry zero reserves. Here's what the filing reveals about the real risk-reward behind a 33.6× P/E.
Cigna Group added $27.8 billion in new revenue in FY 2025 — and generated just $220 million in additional operating income. The 10-K reveals Evernorth's PBS sub-segment margin collapsed 55 basis points to 2.65% as the rebate-free transition extracted ~$722 million in foregone profit, exceeding the company's own $500 million optimization savings target. Meanwhile, CI simultaneously ran a $749 million restructuring program and acquired $548 million in new specialty pharmacy goodwill, funded by a $4.5 billion debt issuance.
Four hospital operators, four business models, 14x ROIC spread. HCA's scale generates 19.2% returns. THC's ambulatory surgery centers deliver 16.8% margins. UHS's behavioral health focus shows improving trends—but deteriorating litigation risk. CYH's rural model is structurally broken. Static ROIC analysis misses the risk velocity layer that determines which returns are sustainable.
Novo Nordisk outearns Eli Lilly on every margin metric: 84.7% gross margin vs 82.9%, 44.2% operating margin vs 44.4%, and 41.7% FCF margin vs ~27%. Yet LLY's 52% ROIC far exceeds NVO's—which appears as an anomalous -3.6%. This isn't a data error: NVO's negative invested capital reveals an extraordinarily asset-light business model where the standard ROIC formula breaks down. For margin-focused investors, NVO wins. For capital efficiency purists, LLY dominates.
Eli Lilly's ROIC doubled from 23% to 52% in 2.5 years as Mounjaro and Zepbound drove 54% revenue growth. Meanwhile, AbbVie's Humira declined 56% to biosimilar competition, testing whether Skyrizi and Rinvoq can fill a $20B revenue gap. This pharma divergence reveals how drug pipelines translate to capital efficiency.